Advertisement
Advertisement
U.S. Markets open in 3 hrs 19 mins
Advertisement
Advertisement
Advertisement
Advertisement

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1000-0.0275 (-21.57%)
At close: 03:49PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1275
Open0.1003
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.1000 - 0.1275
52 Week Range0.0500 - 0.8600
Volume90,127
Avg. Volume68,328
Market Cap3.878M
Beta (5Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    CytRx Corporation Relaunches as LadRx Corporation

    LOS ANGELES, September 23, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.

  • Business Wire

    European Patent Office Awards CytRx Key Patent

    LOS ANGELES, September 07, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.

  • Business Wire

    CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

    LOS ANGELES, August 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the "Board").

Advertisement
Advertisement